Highlights Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-06-05 am EDT			5-day change	1st Jan Change
6.16 ^HKD	-0.81%		+6.57%	-8.47%

Jun. 03	Simcere Pharmaceutical’s Cancer Drug Shows Positive Results	MT
Jun. 03	Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Simcere Pharmaceutical’s Cancer Drug Shows Positive Results	Jun. 03	MT
Simcere Pharma Presents Results of Phase 3 Trial for Anti-Cancer Injection at US Oncology Society Meeting	Jun. 02	MT
Simcere Pharmaceutical Group Limited Announces Phase III Clinical Study of Daridorexant Hydrochloride Tablets in the Treatment of Insomia Patients in China	May. 31	CI
Simcere Pharmaceutical Group Limited and Idorsia Pharmaceuticals Ltd. Announces the Hypnotics Daridorexant Hydrochloride Tablets Obtains the Certificate of Drug/ Product Registration Issued by the Pharmacy and Poisons Board of Hong Kong	May. 22	CI
Simcere Pharmaceutical’ Profit Down 23% in 2023	Apr. 25	MT
Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA	Apr. 09	MT
Simcere Pharmaceutical Group Limited Announces SIM0500 for Injection (a Humanized GPRC5D-BCMA-CD3 Trispecific Antibody) Receives Fast Track Designation by the U.S. Food and Drug Administration	Apr. 09	CI
Simcere Pharmaceutical's 2023 Profit Falls, Misses Estimates; Shares Rise 3%	Mar. 20	MT
Simcere Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended December 31, 2023, Payable on 15 July 2024	Mar. 20	CI
Simcere Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Simcere Pharmaceutical Group's Cancer Drug NDA Accepted by Chinese Regulator	Mar. 17	MT
Simcere Pharmaceutical Group Limited Announces New Drug Application of Suvemcitug for Injection Accepted by the National Medical Products Administration of China	Mar. 15	CI
Simcere Pharmaceutical Group's Cancer Drug Gets China Nod for Clinical Trials	Mar. 13	MT
Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for Sim0500 for Injection (A Humanized Gprc5d-Bcma-Cd3 Trispecific Antibody) Issued by the National Medical Products Administration	Mar. 12	CI
Simcere Pharmaceutical Group Limited Announces Approval of the Investigational New Drug for SIM0500	Mar. 10	CI
Simcere Pharmaceutical Group Limited Announces Findings of A Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in Jama	Feb. 20	CI
Simcere Pharmaceutical’s Profit to Fall Up to 27% in 2023	Feb. 19	MT
Simcere Pharmaceutical Expects Up to 26% Fall in 2023 Profit; Shares Slide 3%	Feb. 19	MT
Simcere Pharmaceutical Group Limited Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	Feb. 18	CI
Simcere Pharmaceutical Group Limited Announces Publication by New England Journal of Medicine About Phase II/III Clinical Studies Results of XIANNUOXIN for Treatment of Adult Patients with Mild-yo-Moderate COVID-19	Jan. 18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Highlights

Filters